New oral anticoagulants, mainly dabigatran and rivaroxaban, are new oral anticoagulants compared to warfarin in China. Compared with warfarin, the risk of cerebral hemorrhage is relatively lower, and there is no need for regular monitoring of INR, or International Normalized Ratio, during the course of medication, and patient compliance will be higher. However, the price of new oral anticoagulants is relatively expensive, and some families with poor financial conditions can hardly afford to choose anticoagulants such as warfarin, and new oral anticoagulants are not an option for atrial fibrillation caused by valve disease.